Vivo Bio Tech Limited (VIVOBIOT) fundamentals
Vivo Bio Tech Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as VIVOBIOT (ISIN INE380K01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Vivo Bio Tech Limited does
Vivo Bio Tech Limited is an India-based company, which is a comprehensive preclinical clinical research organization (CRO) serving pharmaceutical and biotech firms. It operates in the biotechnology segment. It provides integrated discovery, development & regulatory services to pharmaceutical, agrochemical, industrial chemical, vaccines, nutraceutical & medical device companies. The Company's services include in-Vivo and in-Vitro toxicity studies, pharmacological investigations, pharmacokinetic, toxicokinetic studies, genotoxicity screening and analytical services. It screens and assesses molecules for diverse pharmacological properties. In oncology, it designs syngeneic/xenograft models for anti-cancer agent evaluation. It customizes in-Vivo DMPK studies for rodent and non-rodent models to profile drug candidates. It provides both regulatory and non-regulatory IND-enabling preclinical development services.
Valuation and market data
| Last close | ₹17.00 |
|---|---|
| Market capitalisation | ₹26 crore |
| Enterprise value | ₹62 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.33 |
| Price to sales (TTM) | 0.47 |
| Book value per share | ₹50.94 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹53 crore | ₹5 crore | ₹-2 crore | 0.00 |
| Mar 2025 | ₹51 crore | ₹9 crore | ₹8 crore | 4.95 |
| Mar 2024 | ₹45 crore | ₹4 crore | ₹3 crore | 1.69 |
| Mar 2023 | ₹52 crore | ₹5 crore | ₹3 crore | 1.77 |
| Mar 2022 | ₹51 crore | ₹4 crore | ₹2 crore | 1.56 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 30.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 69.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.